Cargando…

Economic Trends in Commonly Used Drugs for Spinal Fusion and Brain Tumor Resection: An Analysis of the Medicare Part D Database

With the incidence of central and peripheral nervous system disorders on the rise, neurosurgical procedures paired with the careful administration of select medications have become necessary to optimize patient outcomes. Despite efforts to decrease the over-prescription of common addictive drugs, su...

Descripción completa

Detalles Bibliográficos
Autores principales: Doad, Jagroop, Gupta, Nithin, Leavitt, Lydia, Hart, Alexandra, Nguyen, Andrew, Kaura, Shawn, DeStefano, Frank, McCray, Edwin, Lucke-Wold, Brandon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452193/
https://www.ncbi.nlm.nih.gov/pubmed/37626682
http://dx.doi.org/10.3390/biomedicines11082185
_version_ 1785095607799513088
author Doad, Jagroop
Gupta, Nithin
Leavitt, Lydia
Hart, Alexandra
Nguyen, Andrew
Kaura, Shawn
DeStefano, Frank
McCray, Edwin
Lucke-Wold, Brandon
author_facet Doad, Jagroop
Gupta, Nithin
Leavitt, Lydia
Hart, Alexandra
Nguyen, Andrew
Kaura, Shawn
DeStefano, Frank
McCray, Edwin
Lucke-Wold, Brandon
author_sort Doad, Jagroop
collection PubMed
description With the incidence of central and peripheral nervous system disorders on the rise, neurosurgical procedures paired with the careful administration of select medications have become necessary to optimize patient outcomes. Despite efforts to decrease the over-prescription of common addictive drugs, such as opioids, prescription costs continue to rise. This study analyzed temporal trends in medication use and cost for spinal fusion and brain tumor resection procedures. The Medicare Part B Database was queried from 2016 to 2020 for data regarding spinal fusion and brain tumor resection procedures, while the Part D Database was used to extract data for two commonly prescribed medications for each procedure. Pearson’s correlation coefficient and linear regression were completed for the analyzed variables. The results showed a significant negative correlation between the number of spinal procedure beneficiaries and the cost of methocarbamol, as well as between the annual percent change in spinal beneficiaries and the annual percent change in oxycodone cost. Linear regression revealed that oxycodone cost was the only parameter with a statistically significant model. Moving forward, it is imperative to combat rising drug costs, regardless of trends seen in their usage. Further studies should focus on the utilization of primary data in a multi-center study.
format Online
Article
Text
id pubmed-10452193
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104521932023-08-26 Economic Trends in Commonly Used Drugs for Spinal Fusion and Brain Tumor Resection: An Analysis of the Medicare Part D Database Doad, Jagroop Gupta, Nithin Leavitt, Lydia Hart, Alexandra Nguyen, Andrew Kaura, Shawn DeStefano, Frank McCray, Edwin Lucke-Wold, Brandon Biomedicines Article With the incidence of central and peripheral nervous system disorders on the rise, neurosurgical procedures paired with the careful administration of select medications have become necessary to optimize patient outcomes. Despite efforts to decrease the over-prescription of common addictive drugs, such as opioids, prescription costs continue to rise. This study analyzed temporal trends in medication use and cost for spinal fusion and brain tumor resection procedures. The Medicare Part B Database was queried from 2016 to 2020 for data regarding spinal fusion and brain tumor resection procedures, while the Part D Database was used to extract data for two commonly prescribed medications for each procedure. Pearson’s correlation coefficient and linear regression were completed for the analyzed variables. The results showed a significant negative correlation between the number of spinal procedure beneficiaries and the cost of methocarbamol, as well as between the annual percent change in spinal beneficiaries and the annual percent change in oxycodone cost. Linear regression revealed that oxycodone cost was the only parameter with a statistically significant model. Moving forward, it is imperative to combat rising drug costs, regardless of trends seen in their usage. Further studies should focus on the utilization of primary data in a multi-center study. MDPI 2023-08-03 /pmc/articles/PMC10452193/ /pubmed/37626682 http://dx.doi.org/10.3390/biomedicines11082185 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Doad, Jagroop
Gupta, Nithin
Leavitt, Lydia
Hart, Alexandra
Nguyen, Andrew
Kaura, Shawn
DeStefano, Frank
McCray, Edwin
Lucke-Wold, Brandon
Economic Trends in Commonly Used Drugs for Spinal Fusion and Brain Tumor Resection: An Analysis of the Medicare Part D Database
title Economic Trends in Commonly Used Drugs for Spinal Fusion and Brain Tumor Resection: An Analysis of the Medicare Part D Database
title_full Economic Trends in Commonly Used Drugs for Spinal Fusion and Brain Tumor Resection: An Analysis of the Medicare Part D Database
title_fullStr Economic Trends in Commonly Used Drugs for Spinal Fusion and Brain Tumor Resection: An Analysis of the Medicare Part D Database
title_full_unstemmed Economic Trends in Commonly Used Drugs for Spinal Fusion and Brain Tumor Resection: An Analysis of the Medicare Part D Database
title_short Economic Trends in Commonly Used Drugs for Spinal Fusion and Brain Tumor Resection: An Analysis of the Medicare Part D Database
title_sort economic trends in commonly used drugs for spinal fusion and brain tumor resection: an analysis of the medicare part d database
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452193/
https://www.ncbi.nlm.nih.gov/pubmed/37626682
http://dx.doi.org/10.3390/biomedicines11082185
work_keys_str_mv AT doadjagroop economictrendsincommonlyuseddrugsforspinalfusionandbraintumorresectionananalysisofthemedicarepartddatabase
AT guptanithin economictrendsincommonlyuseddrugsforspinalfusionandbraintumorresectionananalysisofthemedicarepartddatabase
AT leavittlydia economictrendsincommonlyuseddrugsforspinalfusionandbraintumorresectionananalysisofthemedicarepartddatabase
AT hartalexandra economictrendsincommonlyuseddrugsforspinalfusionandbraintumorresectionananalysisofthemedicarepartddatabase
AT nguyenandrew economictrendsincommonlyuseddrugsforspinalfusionandbraintumorresectionananalysisofthemedicarepartddatabase
AT kaurashawn economictrendsincommonlyuseddrugsforspinalfusionandbraintumorresectionananalysisofthemedicarepartddatabase
AT destefanofrank economictrendsincommonlyuseddrugsforspinalfusionandbraintumorresectionananalysisofthemedicarepartddatabase
AT mccrayedwin economictrendsincommonlyuseddrugsforspinalfusionandbraintumorresectionananalysisofthemedicarepartddatabase
AT luckewoldbrandon economictrendsincommonlyuseddrugsforspinalfusionandbraintumorresectionananalysisofthemedicarepartddatabase